Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a strong-buy rating in a report released on Saturday morning.

Several other equities research analysts have also recently commented on the company. Craig Hallum set a $65.00 price target on Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Friday, March 27th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $62.17.

Supernus Pharmaceuticals Trading Down 1.4%

SUPN stock opened at $51.53 on Friday. The company has a market capitalization of $2.99 billion, a P/E ratio of -101.04, a PEG ratio of 0.89 and a beta of 0.57. Supernus Pharmaceuticals has a twelve month low of $30.83 and a twelve month high of $59.68. The business has a 50 day simple moving average of $51.11 and a 200-day simple moving average of $49.93.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 7,250 shares of the company’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $49.60, for a total transaction of $359,600.00. Following the completion of the sale, the vice president owned 17,044 shares in the company, valued at $845,382.40. This represents a 29.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bethany Sensenig sold 4,475 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $51.01, for a total value of $228,269.75. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 120,881 shares of company stock valued at $6,139,356. Corporate insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Hantz Financial Services Inc. raised its position in Supernus Pharmaceuticals by 81.7% in the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 281 shares in the last quarter. Rockefeller Capital Management L.P. raised its position in Supernus Pharmaceuticals by 354.8% in the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after acquiring an additional 660 shares in the last quarter. Torren Management LLC purchased a new position in Supernus Pharmaceuticals in the fourth quarter worth $49,000. EverSource Wealth Advisors LLC purchased a new position in Supernus Pharmaceuticals in the second quarter worth $51,000. Finally, Smartleaf Asset Management LLC raised its position in Supernus Pharmaceuticals by 30.8% in the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after acquiring an additional 268 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.